Trial · NCT03060993
CAN BREATHE in COPD Trial
NCT03060993, Phase 2, Unknown, McGill University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CAN BREATHE in COPD Trial. Trials, record NCT03060993. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03060993
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CAN BREATHE in COPD Trial
- NCT number
- NCT03060993
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 16 participants, estimated
- Lead sponsor
- McGill University
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Breathlessness, Exercise Intolerance
- Interventions
- Cannabis, Placebo
- First posted
- 2017-02-23
- Last updated
- 2017-02-23
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in intensity ratings of perceived breathlessness at isotime during cycle exercise testing. | Participants will be followed until all study visits are complete, an expected average of 4 weeks | Patients will be required to rate the intensity of their breathlessness using Borg's modified 0-10 category ratio scale every 2-minutes during cycle exercise testing. |
| Primary | Changes in cycle exercise endurance time. | Participants will be followed until all study visits are complete, an expected average of 4 weeks | Exercise endurance time will be defined as the duration of loaded pedaling during the constant-load cycle exercise testing performed at 75% of peak incremental power output. |
| Secondary | Changes in Spirometry | Participants will be followed until all study visits are complete, an expected average of 4 weeks | Spirometry will be performed before and 5-min after treatment administration |
| Secondary | Changes in Impulse oscillometry | Participants will be followed until all study visits are complete, an expected average of 4 weeks | Impulse oscillometry will be performed before and 10-min after treatment administration |
| Secondary | Changes in Physiological responses during exercise. | Participants will be followed until all study visits are complete, an expected average of 4 weeks | Gas exchange, cardiovascular and breathing pattern variables will be collected breath-by-breath and averaged in 30-sec epochs during incremental and constant-load cycle exercise tests. |
| Secondary | Plasma cannabinoid levels. | Participants will be followed until all study visits are complete, an expected average of 4 weeks | Venous blood samples for the determination of circulating levels of cannabinoids will be collected before and 2-, 30-, 75-, and 180-min after vaporization |
| Secondary | Psychoactive effects. | Participants will be followed until all study visits are complete, an expected average of 4 weeks | Psychoactive effects of cannabis will be evaluated during each treatment visit using 100-mm visual analogue scale (VAS). Psychoactive effects will be evaluated before and 45-min after treatment administration. |
| Secondary | Mood effects. | Participants will be followed until all study visits are complete, an expected average of 4 weeks | Mood effects of cannabis will be evaluated during each treatment visit using 100-mm visual analogue scale (VAS). Mood effects will be evaluated before and 45-min after treatment administration. |
| Secondary | Cognitive effects. | Participants will be followed until all study visits are complete, an expected average of 4 weeks | Cognitive effects will be measured during each treatment visit using the mini-mental state exam. The mini-mental state exam will be administered before and 45-min after treatment administration |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30049223 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03060993
GET https://conductscience.org/api/trials/v1/NCT03060993/registered